Investigate / BAX
Understand BAXTER INTERNATIONAL INC
Can Baxter's smaller, reorganized portfolio sustain its operations while resolving the Novum LVP shipment hold and working through restructuring?
Snapshot reviewed 2026-10-02. Source published 2026-07-30. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / BAX
Ask better questions. Keep the evidence.
Explore the available sources for BAXTER INTERNATIONAL INC, then keep what deserves another look.
01 Investor activity
Who reports owning BAX?
9 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Baxter sells essential hospital and care-setting products, including IV solutions, infusion systems, parenteral nutrition, generic injectables, smart beds and patient monitoring, to hospitals, nursing homes, surgery centers, clinics and home patients.
Latticework interpretation
What could support the case?
If the new operating model and continuous-improvement system work as intended, Baxter could better align decision-making, cost structure and commercial execution across its remaining businesses.
Latticework interpretation
What could break the case?
If the Novum LVP shipment and installation hold continues, uncertain release timing could prolong the period without meaningful sales of that product.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Baxter sells essential hospital and care-setting products, including IV solutions, infusion systems, parenteral nutrition, generic injectables, smart beds and patient monitoring, to hospitals, nursing homes, surgery centers, clinics and home patients.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $2,960m | $2,810m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $217m | $191m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $126m | $91m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $498m | $24m |
Comparison caveat: Revenue and operating income cover continuing operations, while the selected net income and cash flow include discontinued Kidney Care. Inspect both scopes rather than assuming unchanged-business comparisons.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If the new operating model and continuous-improvement system work as intended, Baxter could better align decision-making, cost structure and commercial execution across its remaining businesses.
Supporting filing ↗The strongest caution
If the Novum LVP shipment and installation hold continues, uncertain release timing could prolong the period without meaningful sales of that product.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
What is needed to lift the Novum LVP hold?
Starting evidence: Some identified corrections may require regulatory clearance or approval and are in early verification testing, so the release timing remains uncertain.
Investigate next: Review later filings and FDA communications for correction status, approval needs, and any announced timeline for resuming shipments.
Read the supporting filing ↗Will restructuring offset the dis-synergies from the smaller company?
Starting evidence: Baxter has incurred and expects additional dis-synergies from the Kidney Care sale due to its reduced size, and has undertaken and intends further restructuring actions.
Investigate next: Compare restructuring charges, remaining planned actions, and cost-structure commentary across upcoming quarterly reports.
Read the supporting filing ↗How exposed is Baxter to supply chain and trade policy changes?
Starting evidence: Weather and geopolitical events have challenged Baxter’s global supply chain and negatively affected results, with potential future effects.
Investigate next: Examine disclosures on tariff exposure, refund recoveries, supplier concentration and supply disruption effects on cost of goods sold.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.